Mr. Hugh MacNaught reports

VENTRIPOINT DIAGNOSTICS APPOINTS THOMAS BROWN AS DIRECTOR OF CONGENITAL HEART DEFECT PROGRAM

Ventripoint Diagnostics Ltd. has appointed Thomas Brown, former vice-president of North American sales at Intelligent Ultrasound, as director of the congenital heart defect program.

Mr. Brown brings more than 20 years of leadership experience in global medical imaging sales, commercialization and market expansion. At Intelligent Ultrasound, he drove significant international growth, launching artificial-intelligence-powered imaging solutions into both clinical and training markets.

This appointment is a strategic move to accelerate Ventripoint's market leadership in the congenital heart defect segment -- one of the largest and fastest-growing areas in pediatric cardiology -- with the potential to expand adoption of VMS+ into related high-value markets such as cardio-oncology, pulmonary hypertension, heart failure and valve disease.

"Thomas's expertise in scaling innovative imaging solutions will be a catalyst for growth in our CHD program and beyond," said Hugh MacNaught, president and chief executive officer of Ventripoint Diagnostics. "This is a key step in executing our multisegment growth strategy."

Ventripoint's VMS+ technology enables accurate, MRI-comparable cardiac volumetric analysis using standard 2-D cardiac ultrasound -- dramatically reducing costs, eliminating wait times, and expanding access for clinicians and patients.

Mr. Brown's career spans over 20 years in health care technology sales and market development, with a focus on introducing innovative imaging solutions into clinical practice. At Intelligent Ultrasound, he was responsible for significant revenue growth, international market expansion and the launch of cutting-edge AI products into the health care ecosystem.

"I'm excited to join Ventripoint at such a pivotal time in the company's growth," said Mr. Brown. "The potential of Ventripoint's artificial-intelligence-powered solutions to transform how congenital heart defects are diagnosed and monitored is tremendous, and I look forward to working with the team to bring this vision to life."

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of artificial intelligence to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development, and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.